ROIV Stock Price Today (July 2026) — Roivant Sciences Ltd. Analysis & Key Metrics 2026-07-17
Roivant Sciences Ltd. (ROIV) is trading at $34.51, up 1.71% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $39.04 (13.1% upside).
- Volatility remains elevated (26.80% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-66.70% YoY) alongside significant competitive pressures.
ROIV Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Roivant Sciences Ltd. - Historical Price & Volume
Market Cap
Enterprise Value: $22.04B
P/E Ratio
Forward P/E: -22.70
Revenue Growth
Year over Year
Analyst Target
+13.1% upside potential
Key Investor Questions About ROIV
What investors need to know before buying
Based on current market data, ROIV presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 51.79)
- Fundamentals say: Challenging (declining revenue trends)
ROIV's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ROIV investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $107.44M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ROIV stock traded between $10.71 and $35.90—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 26.80% annualized volatility and β=0.94, the stock exhibits moderate correlation to market moves—making ROIV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
Arbutus expects to receive around $179 million from Moderna.
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
Wall Street expects sales to soar as several commercial launches approach.
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On May 20, Roivant Sciences reported its financial results for FQ4 and the full year FY2026, alongside a comprehensive business update. The company finished the year with $4.3 billion in consolidated cash and marketable securities, providing a runway into […]
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC). Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving […]
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks to buy with highest upside potential. Guggenheim lifted the price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $36 from $30 on May 26 and maintained a Buy rating on the shares, updating its model after the recent fiscal Q4 earnings and pipeline updates. The stock […]
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum
Roivant Sciences stock performance snapshot Roivant Sciences (ROIV) has drawn investor attention recently after its share price closed at US$29.96, with total return around 9% over the past month and about 5% over the past 3 months. See our latest analysis for Roivant Sciences. While the share price slipped about 3% over the last day, Roivant Sciences still has a 36.62% year to date share price return and a very large 1 year total shareholder return, suggesting recent momentum follows a much...
TD Cowen Raises its Price Target on Roivant Sciences (ROIV)
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 15 High Growth Stocks to Buy and Hold for the Next Decade. On May 21, 2026, TD Cowen raised the firm’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $41 from $38 and maintained a Buy rating on the shares. TD Cowen said IMVT-1402 toplined impressive Ph2b […]
Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)
In May 2026, Roivant Sciences reported fourth-quarter 2026 results showing sales of US$2.52 million, a swing to quarterly net income of US$302.99 million, and full-year 2026 sales of US$8.26 million alongside a wider annual net loss of US$299.77 million. The earnings were heavily influenced by a US$770.2 million litigation settlement gain linked to Genevant’s US$2.25 billion global patent settlement with Moderna, highlighting how non-operating items and asset monetization can meaningfully...
Roivant (ROIV) Climbs 15% on Swing to Profits
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 10 Stocks With Insane Returns Right Now. Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors took heart from its swing to profitability in the fourth quarter of fiscal year 2026, while positioning portfolios ahead of the launch […]
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $34.51. The RSI (14-day) is at 51.8, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $39.04 implies 13.1% upside from current levels. Volatility is moderate at 26.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is -63.91, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -22.70. Price-to-Book is 5.49. Price-to-Sales is 3005.09. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering ROIV, the consensus price target is $39.04. This represents a 13.1% upside from the current price of $34.51. The range spans from a low target of $31.50 to a high target of $45.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. Moderate volatility (26.8% annualized)—price swings are notable. 2. Declining revenue (-66.7% YoY), indicating potential business headwinds. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $107.44M. The debt-to-equity ratio is 2.03, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 18.37, indicating strong short-term liquidity. The quick ratio is 18.00. The company holds $4.29B in cash and equivalents. Free cash flow is negative at $-1,090,485,376, which could limit the company's ability to manage debt obligations.